Core Viewpoint - Sanofi Pharmaceutical (01530) experienced a decline of over 8%, specifically 8.33%, trading at HKD 29.7 with a transaction volume of HKD 495 million following the announcement of a proposed spin-off of its subsidiary, Mandi [1] Group 1: Company Announcement - On November 20, Sanofi Pharmaceutical announced its proposal to spin off its subsidiary, Mandi, for independent listing on the Hong Kong Stock Exchange [1] - The proposed spin-off is expected to be executed through a physical distribution of Mandi shares to shareholders based on their respective holdings in the company, along with a global offering of new Mandi shares [1] - Mandi International submitted its listing application to the Hong Kong Stock Exchange yesterday [1] Group 2: Ownership Structure - As of the announcement date, Mandi is beneficially owned by Sanofi Pharmaceutical (approximately 87.16%), Yingtai Management Limited (3.38%), Mandi Group Limited (2.80%), GL Wecan Investment IV L.P. (4.00%), and Alibaba Health (Hong Kong) Technology Co., Ltd. (2.65%) [1] Group 3: Mandi's Market Position - Mandi focuses on the hair health sector within the broader skin health industry and has established a leading position [1] - Mandi launched the first domestic 5% minoxidil solution under the Mandi® brand in 2001 and plans to introduce a second-generation minoxidil product, Mandi® 5% minoxidil foam, in 2024 [1]

Group 1: Market Overview - The Hang Seng Index closed slightly up by 4 points or 0.02%, after fluctuating throughout the day, with a high of 25,999 and a low of 25,692 [3][4] - The total market turnover was 245.136 billion, with a net inflow of 15.992 billion from northbound trading [3] - Among 88 blue-chip stocks, 55 saw an increase, while technology stocks continued to show weakness [4] Group 2: Economic Indicators - Hong Kong's inflation rate for October was reported at 1.2%, slightly higher than September's 1.1%, aligning with expectations [7] - The basic inflation rate, excluding government relief measures, remained at 1% [7] - The government indicated that overall inflation is expected to remain mild in the short term due to controlled price pressures [7] Group 3: Corporate News - Sanofi plans to spin off its subsidiary, Mandai, for independent listing on the Hong Kong Stock Exchange, aiming to enhance growth positioning for both entities [11] - Xinyi Energy announced the sale of a 51% stake in a photovoltaic power plant in Tianjin for 515 million RMB, with proceeds allocated for general operational funds [13] - Amax Holdings intends to acquire the Parisian Macao hotel for 1.75 billion HKD, with part of the funds used to repay bank loans [14]

Group 1 - The Hong Kong stock market saw a collective decline in the innovative drug sector, with notable drops in several companies [1] - Three-Sixty Pharmaceutical experienced a decline of over 7% [1] - Other companies such as King’s Ray Biotechnology, CSPC Pharmaceutical Group, and Galenica also reported declines [1]

Market Performance - A-shares adjusted with the Shanghai Composite Index down 0.4% to 3931.05 points, Shenzhen Component down 0.76%, and ChiNext down 1.12%[1] - Hong Kong's Hang Seng Index closed up 0.02% at 25835.57 points, while the Hang Seng Tech Index fell 0.58%[1] - The total market turnover in Hong Kong was 2451.357 million HKD[1] Employment Data - The U.S. added 119,000 jobs in September, but the unemployment rate rose to 4.4%, the highest in nearly four years[8][13] - Job growth was concentrated in healthcare, entertainment, and hospitality, while manufacturing and business services saw job losses[13] Inflation and Interest Rate Outlook - Multiple Federal Reserve officials warned about inflation risks, making the outlook for interest rate cuts uncertain before year-end[1][13] - The market currently estimates a 40% chance of a rate cut in December[13] Geopolitical Tensions - China rejected Japan's statements regarding Taiwan and reiterated demands for the Japanese Prime Minister to retract his comments[1][13] - The U.S. expressed support for Japan in any disputes with China, indicating ongoing geopolitical tensions[8][13]

Market Overview - The Hang Seng Index is expected to find short-term support around the 100-day moving average at approximately 25,600 points due to a hawkish stance from the Federal Reserve and ongoing uncertainties in the US-China trade relations [2] - The recent meeting between the US and Chinese leaders has led to a temporary easing of tensions, but core issues remain unresolved [2] - China's economic slowdown in Q3 has prompted the government to focus on expanding domestic demand and promoting technological self-reliance [2] Macro Focus - China is reportedly considering new support policies for the real estate sector, including interest subsidies for housing loans [4][10] - The government has announced a maximum funding of 400 million yuan to support 50 cities in developing new consumption models [10] - The US added 119,000 non-farm jobs in September, exceeding expectations, while the unemployment rate slightly increased to 4.4% [10] Corporate News - NetEase reported a 27% increase in adjusted profit for Q3, meeting expectations, but revenue growth of 8% fell short [5][11] - ByteDance's valuation has reportedly risen to $480 billion following a competitive auction for shares [11] - Xiaomi has produced its 500,000th vehicle in just 19 months, marking a significant milestone for the company [11] Sector Insights - The insurance sector is expected to benefit from strong investment returns in Q3 due to robust A-share performance [9] - Coal stocks are anticipated to see upward price momentum for thermal coal [9] - Lithium industry stocks are optimistic about a recovery in lithium carbonate demand, with supply and demand expected to balance [9]

Core Viewpoint - Mandi International is a leading professional consumer pharmaceutical company in China, focusing on comprehensive and long-term solutions for skin health and weight management, with a strong emphasis on hair health [1] Company Overview - Mandi International has submitted its application to the Hong Kong Stock Exchange for a mainboard listing, with Huatai International as its sole sponsor [1] - The company has established a leading position in the hair health sector within the broader skin health industry [1] Product and Market Position - Mandi's flagship product, the Mandi series minoxidil hair loss treatment, has ranked first in the Chinese hair loss drug market for ten consecutive years since 2014, with market shares of approximately 57% and 71% in the hair loss and minoxidil drug markets, respectively, projected for 2024 [2] - The products are distributed through over 2,000 medical institutions and approximately 190,000 retail pharmacies, covering more than 90% of China's top 100 chain pharmacies [2] - Mandi has established an O2O model through leading instant retail platforms, enhancing product accessibility for consumers [2] Research and Development - Mandi International is expanding its pipeline in the hair health sector, with plans to launch a 5% minoxidil foam in Europe by 2026 and a clinical project focused on female androgenetic alopecia in China, expected to enter Phase III trials by December 2024 [2][3] - The company is also developing a targeted monoclonal antibody for androgenetic alopecia and has initiated clinical trials for a topical androgen receptor inhibitor for acne [3] Financial Performance - The company's revenue for the fiscal years 2022, 2023, and 2024 is approximately RMB 982 million, RMB 1.228 billion, and RMB 1.455 billion, respectively, with a profit of RMB 202 million, RMB 341 million, and RMB 390 million for the same periods [4][6] - The gross profit margin for the years 2022, 2023, and 2024 is reported at 80.3%, 82.0%, and 82.7%, respectively [7][9] Industry Overview - The skin health market in China is rapidly growing, projected to increase from RMB 53.7 billion in 2018 to RMB 142.5 billion by 2024, with a CAGR of 17.7% [10] - The number of individuals suffering from hair loss in China is expected to rise from 271 million in 2018 to 339 million in 2024, with a CAGR of 3.8% [12] - The minoxidil market in China is anticipated to grow from RMB 200 million in 2018 to RMB 2.8 billion by 2024, with a CAGR of 50.9% [12] - The obesity drug market in China is also expanding, projected to grow from RMB 800 million in 2018 to RMB 2.3 billion by 2024, with a CAGR of 20.7% [15]

Core Insights - Three innovative drugs have made significant progress, potentially stabilizing the Hang Seng Biotechnology Index and the Hang Seng Innovative Drug Index [1] Group 1: Drug Developments - Innovent Biologics announced that its drug IBI362 (Mastuzumab Injection) has achieved primary and all key secondary endpoints in a Phase III clinical trial for moderate to severe obesity in China, with plans to submit a new drug application for weight control [1] - Junshi Biosciences' PD-1 inhibitor, H drug (Surulitinib), has been officially included in the NMPA's list of breakthrough therapies for perioperative treatment of gastric cancer, marking it as the first drug recognized for this indication [2] - Peijia Medical's PB-119 has received approval from the NMPA for its new drug application, leveraging unique PEGylation technology to enhance efficacy while reducing immunogenicity and gastrointestinal side effects [3] Group 2: Industry Trends - The introduction of the innovative drug directory by commercial insurance is expected to address the accessibility and affordability of high-priced innovative drugs, with policies increasingly favoring the development of high-quality innovative drugs [3] - Chinese innovative pharmaceutical companies are increasingly focusing on internationalization, transitioning from imitation to innovation, supported by favorable policies and abundant clinical resources [2][3] - The ongoing drug review reforms are releasing dividends that are propelling the Chinese innovative drug industry into a new era of "innovation output" [2]

Group 1 - Three innovative drugs have made significant progress, potentially stabilizing the Hang Seng Biotechnology Index and the Hang Seng Innovative Drug Index [1] - Innovent Biologics announced that its drug IBI362 has achieved primary and all key secondary endpoints in a Phase III clinical trial for obesity, with plans to submit a new drug application for weight control [1] - The drug IBI362 is a dual receptor agonist for glucagon and GLP-1, and is the first of its kind approved globally for obesity and type 2 diabetes management [1] Group 2 - Junshi Biosciences' PD-1 inhibitor, H drug, has been officially included in the breakthrough therapy list by the NMPA for use in perioperative treatment of gastric cancer, marking a significant recognition of its clinical value [2] - This breakthrough designation is expected to accelerate the review and approval process for H drug, filling a gap in immune therapy for gastric cancer [2] - The approval of PB-119 by the NMPA highlights the competitive advantage of the drug based on solid clinical data and innovative PEGylation technology, which balances efficacy and reduces side effects [1][3] Group 3 - The introduction of the innovative drug directory by commercial insurance is expected to address the accessibility and affordability of high-priced innovative drugs [3] - The National Healthcare Security Administration is encouraging the high-quality development of innovative drugs, indicating a warming trend in payment policies for innovative drugs [3] - Domestic pharmaceutical companies are actively transitioning towards innovation, supported by ongoing reforms in drug approval processes [3] Group 4 - Relevant Hong Kong stocks in the innovative drug sector include Heng Rui Medicine, Kelun-Botai Biopharmaceutical, and others, indicating a growing interest in the market [4]

Major Events - Sanofi Pharmaceutical (01530) proposes to spin off Mandi International and independently list it on the main board of the Hong Kong Stock Exchange [1] - Youbao Online (02429) signs a trusted asset management platform service agreement with Ant Chain Technology [1] - Jianxi Technology-B (09877) reports 6-month clinical follow-up results for LuX-Valve Plus TRINITY study on patients with large valve rings [1] - Fuhong Hanlin (02696) announces that Hanshu® (Sru Li monoclonal antibody injection) combined with chemotherapy for gastric cancer neoadjuvant/adjuvant treatment has been officially included in the breakthrough therapy drug program by the National Medical Products Administration [1] - Kaizhile International (02122) partners with globally renowned toy company Jazwares to launch HELLO KITTY AND FRIENDS toys [1] Operating Performance - ZTO Express-W (02057) reports third-quarter net profit attributable to shareholders of 2.524 billion yuan, an increase of 5.32% year-on-year [1] - Lenovo Group (00992) announces interim results with a profit attributable to shareholders of 846 million USD, a year-on-year growth of 40% [1] - CSPC Pharmaceutical Group (01093) releases third-quarter results showing a profit attributable to shareholders of 3.511 billion yuan, a decrease of 7.06% year-on-year [1] - NetEase-S (09999) reports third-quarter net profit attributable to shareholders of approximately 8.616 billion yuan, a year-on-year increase of 31.77%, with a dividend of 0.114 USD per share [1] - Jingyou Pharmaceutical (00858) issues a profit warning, expecting a mid-term loss of approximately 450 million to 480 million HKD, transitioning from profit to loss year-on-year [1]

Group 1 - The company proposes to spin off its subsidiary, Mandi Co., and list it independently on the Hong Kong Stock Exchange [1] - The proposed spin-off will involve a distribution of all shares of Mandi to shareholders based on their ownership percentage and a global offering of new Mandi shares [1] - The Hong Kong Stock Exchange has confirmed that the company can proceed with the proposed spin-off [1] Group 2 - Upon completion of the spin-off, the company will no longer retain any interests in Mandi, and Mandi will cease to be a subsidiary of the company [1] - Mandi submitted an application to the Hong Kong Stock Exchange on November 20, 2025, for the approval of its shares to be listed and traded on the main board [1] - The listing document for Mandi is expected to be published on the Hong Kong Stock Exchange's website for review and download [1]